Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebola post-exposure prophylaxis trial in high-risk contacts
PACTR202502853321394Phase 3Not yet recruiting
- Sponsor
- ANRS
- Start
- Jul 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of Ebola Zaire vaccine (live, attenuated), REGN-EB3 and obeldesivir in Ebola virus disease (EVD) (3 arms), sponsored by ANRS. Primary endpoint: Rate of Ebola virus disease at day 21. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
Ebola Zaire vaccine (live, attenuated)REGN-EB3obeldesivir
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR202502853321394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202502853321394.